| Literature DB >> 19816091 |
Xin Liu1, Emily K Y Lam, Xian Wang, Jianbin Zhang, Yuen Yee Cheng, Yun W Lam, Enders K O Ng, Jun Yu, Francis K L Chan, HongChuan Jin, Joseph J Y Sung.
Abstract
As an important way to inactivate tumor suppressor genes (TSGs) during cancer development, promoter hypermethylation can be used to define novel TSGs and identify biomarkers for cancer diagnosis. SLC19A3 (solute carrier family 19, member 3) was found to be such a biomarker. SLC19A3 expression was downregulated in gastric cancer cell lines (71%, 5/7) and restored after pharmacological demethylation. Notably, hypermethylation of SLC19A3 promoter was detected in gastric cancer cell lines (57%, 4/7), primary gastric carcinoma tissues (51%, 52/101) and precancerous lesion (intestinal metaplasia) tissues (32%, 8/25). Exogenous SLC19A3 expression caused growth inhibition of gastric cancer cells. In summary, SLC19A3 was epigenetically downregulated in gastric cancer. Methylation of SLC19A3 promoter could be a novel biomarker for early gastric cancer development. (c) 2009 S. Karger AG, Basel.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19816091 DOI： 10.1159/000243767
Source DB: PubMed Journal: Tumour Biol ISSN： 1010-4283